Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Obsessive-compulsive disorder is one of the most treatment-resistant conditions in psychiatry. While SSRIs and exposure-response prevention therapy are effective for many patients, an estimated 40% to 60% of people with OCD do not achieve adequate symptom relief with first-line treatments. For those patients, options narrow quickly. A 2013 proof-of-concept trial at Columbia University asked whether ketamine — already showing promise in depression — could rapidly reduce obsessive-compulsive symptoms.
Carolyn Rodriguez and colleagues conducted a randomized, double-blind, placebo-controlled crossover trial, published in Neuropsychopharmacology in 2013. Fifteen medication-free adults with near-constant obsessive-compulsive symptoms received a single intravenous infusion of ketamine (0.5 mg/kg over 40 minutes) and saline placebo on separate occasions, with a washout period of at least one week between infusions.
The primary outcome was change in OCD symptom severity measured by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). The results showed that ketamine produced a rapid and significant reduction in obsessive-compulsive symptoms compared to placebo. By 230 minutes after infusion, 50% of ketamine-treated patients met response criteria (at least 35% reduction in Y-BOCS). One week post-infusion, some patients continued to show sustained improvement, though effects were beginning to fade in others.
Notably, the anti-obsessional effects were not fully explained by reductions in comorbid depression or anxiety. This suggests that ketamine may act on neurobiological mechanisms specific to OCD, not merely alleviating distress that worsens obsessive thinking. The crossover design, in which each patient served as their own control, added rigor despite the small sample size.
OCD is thought to involve dysfunction in cortico-striato-thalamo-cortical (CSTC) circuits — the brain pathways connecting the prefrontal cortex, basal ganglia, and thalamus. Glutamate is a primary neurotransmitter in these circuits, and there is growing evidence that glutamatergic dysregulation may be a core feature of OCD pathophysiology. This makes ketamine's mechanism of action — NMDA receptor antagonism and downstream glutamate modulation — particularly relevant.
From a physician's standpoint, the Rodriguez trial is important not because it establishes ketamine as a treatment for OCD, but because it provides proof of concept that targeting the glutamate system can rapidly reduce OCD symptoms. This opens a research direction that may lead to new treatments. For patients with severe, treatment-resistant OCD who have exhausted standard options, the rapid onset of ketamine's effects is especially notable — standard anti-OCD medications like high-dose SSRIs can take 8 to 12 weeks to reach full effect.
Ketamine is not FDA-approved for the treatment of OCD, and the evidence remains preliminary. Larger trials are needed before definitive conclusions can be drawn.
If you live with OCD that has not responded to medication and therapy, the Rodriguez et al. study suggests that glutamate-targeted approaches may represent a new frontier. Ketamine is not yet established as a standard OCD treatment, and the research is at an early stage. However, for some patients, ketamine therapy prescribed off-label may be worth discussing with a physician who is familiar with both the potential benefits and the limitations of the current evidence.
Many patients with treatment-resistant OCD also experience comorbid depression and anxiety. Ketamine's potential to address multiple symptom domains through a single mechanism makes it a particularly interesting option for patients dealing with overlapping conditions.
A proof-of-concept crossover trial found that a single dose of ketamine rapidly reduced obsessive-compulsive symptoms in patients with near-constant OCD, with effects partially independent of changes in mood. While the evidence is preliminary and ketamine is not FDA-approved for OCD, this study supports further investigation of glutamate-targeted treatments for this challenging condition.
Reference: Rodriguez CI, Kegeles LS, Levinson A, et al. "Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept." Neuropsychopharmacology. 2013;38(12):2475-2483. PMID: 23903029
If you're considering ketamine therapy, Isha Health offers physician-led at-home treatment via telemedicine in California, New York, Texas, Florida, Colorado, Arizona, Georgia, Oregon, and Washington. No in-person visit required.
